Suppr超能文献

联合使用高敏心肌肌钙蛋白 T 和 N 末端脑利钠肽前体可改善慢性心力衰竭患者的预后,优于传统的死亡风险因素。

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

机构信息

Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, Spain.

出版信息

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

Abstract

BACKGROUND

Heart failure still maintains a high mortality. Biomarkers reflecting different pathophysiological pathways are under evaluation to better stratify the mortality risk. The objective was to assess high-sensitivity cardiac troponin T (hs-cTnT) in combination with N-terminal pro-B type natriuretic peptide (NT-proBNP) for risk stratification in a real-life cohort of ambulatory heart failure patients.

METHODS

We analyzed 876 consecutive patients (median age 70.3 years, median left ventricular ejection fraction 34%) treated at a heart failure unit. A combination of biomarkers reflecting myocyte injury (hs-cTnT) and myocardial stretch (NT-proBNP) was used in addition to an assessment based on established mortality risk factors (age, sex, left ventricular ejection fraction, New York Heart Association functional class, diabetes, estimated glomerular filtration rate, ischemic etiology, sodium, hemoglobin, β-blocker treatment, and angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment).

RESULTS

During a median follow-up of 41.4 months, 311 patients died. In the multivariable Cox proportional hazards model, hs-cTnT and NT-proBNP were independent prognosticators (P = .003 each). The combined elevation of both biomarkers above cut-off values significantly increased the risk of death (HR 7.42 [95% CI, 5.23-10.54], P < .001). When hs-cTnT and NT-proBNP were individually included in a model with established mortality risk factors, measurements of performance significantly improved. Results obtained for hs-cTnT compared with NT-proBNP were superior according to comprehensive discrimination, calibration, and reclassification analysis (net reclassification indices of 7.7% and 1.5%, respectively).

CONCLUSIONS

hs-cTnT provides significant prognostic information in a real-life cohort of patients with chronic heart failure. Simultaneous addition of hs-cTnT and NT-proBNP into a model that includes established risk factors improves mortality risk stratification.

摘要

背景

心力衰竭仍然存在较高的死亡率。目前正在评估反映不同病理生理途径的生物标志物,以更好地对死亡率风险进行分层。本研究旨在评估高敏心肌肌钙蛋白 T(hs-cTnT)与 N 末端脑利钠肽前体(NT-proBNP)联合应用于门诊心力衰竭患者的风险分层。

方法

我们分析了在心力衰竭病房接受治疗的 876 例连续患者(中位年龄 70.3 岁,中位左心室射血分数 34%)。除了基于已确立的死亡率危险因素(年龄、性别、左心室射血分数、纽约心脏协会功能分级、糖尿病、估计肾小球滤过率、缺血性病因、钠、血红蛋白、β受体阻滞剂治疗、血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂治疗)进行评估外,还使用了反映心肌损伤(hs-cTnT)和心肌拉伸(NT-proBNP)的生物标志物组合。

结果

在中位随访 41.4 个月期间,有 311 例患者死亡。在多变量 Cox 比例风险模型中,hs-cTnT 和 NT-proBNP 是独立的预后指标(P 均<.003)。两个生物标志物水平均高于截断值的联合升高显著增加了死亡风险(HR 7.42[95%CI,5.23-10.54],P<.001)。当 hs-cTnT 和 NT-proBNP 分别包含在包含已确立死亡率危险因素的模型中时,测量结果的性能显著提高。根据综合判别、校准和重新分类分析,hs-cTnT 的结果优于 NT-proBNP(净重新分类指数分别为 7.7%和 1.5%)。

结论

hs-cTnT 为慢性心力衰竭患者的真实队列提供了重要的预后信息。在包含已确立风险因素的模型中同时加入 hs-cTnT 和 NT-proBNP 可改善死亡率风险分层。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验